Market Cap 2.04B
Revenue (ttm) 0.00
Net Income (ttm) -105.04M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 4,063.20
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 756,612
Avg Vol 1,326,642
Day's Range N/A - N/A
Shares Out 57.84M
Stochastic %K 61%
Beta 0.48
Analysts Strong Sell
Price Target $54.67

Company Profile

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial t...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 727 1755
Address:
10865 Road to the Cure, Suite 150, San Diego, United States
nickiead
nickiead Apr. 28 at 9:01 PM
$CAPR Makary says search has gone extremely well with some terrific candidates. His preference, according to several sources is Hemmati, so I expect he will get the position.
1 · Reply
UncleB13
UncleB13 Apr. 28 at 8:02 PM
$CAPR as I suspected
8 · Reply
Macme
Macme Apr. 28 at 7:35 PM
$CAPR Late spike? Let’s see
0 · Reply
bronx24bomber
bronx24bomber Apr. 28 at 7:04 PM
$CAPR This has gone from green to red in the last hour on multiple occasions. Lets hope we get the opposite today.
0 · Reply
WBinthehouse
WBinthehouse Apr. 28 at 6:58 PM
$CAPR The highest price ever paid for a Priority Review Voucher is $350 million. This record was set in 2015 when AbbVie purchased a Rare Pediatric Disease PRV from United Therapeutics. PRVs are FDA issued vouchers that allow a company to receive priority FDA review for a new drug application, and they can be sold or transferred to other companies. They are especially valuable for rare disease drugs or certain tropical disease treatments.
1 · Reply
wkee
wkee Apr. 28 at 6:42 PM
$CAPR get your popcorn !! 🍿
1 · Reply
Atmwireless
Atmwireless Apr. 28 at 6:40 PM
0 · Reply
aricray
aricray Apr. 28 at 6:40 PM
$CAPR added
0 · Reply
ys95
ys95 Apr. 28 at 6:36 PM
$CAPR well looks like we are finally gonna hit the 3month trendline. Good news is, it now sits at $33.40ish. (It’s moved up a bunch these past couple of weeks) it would also be great if we only get close and not touch it. Time will tell.
0 · Reply
Marthvadir
Marthvadir Apr. 28 at 6:32 PM
$CAPR Added 40
0 · Reply
Latest News on CAPR
Capricor Therapeutics Earnings Call Transcript: Q4 2025

Mar 12, 2026, 4:30 PM EDT - 6 weeks ago

Capricor Therapeutics Earnings Call Transcript: Q4 2025


Capricor Therapeutics Transcript: Study Result

Dec 17, 2025, 1:00 PM EST - 4 months ago

Capricor Therapeutics Transcript: Study Result


Capricor Therapeutics Transcript: Status Update

Dec 3, 2025, 8:00 AM EST - 5 months ago

Capricor Therapeutics Transcript: Status Update


Martin Shkreli Takes Aim At Capricor — Stock Sinks

Nov 24, 2025, 1:49 PM EST - 5 months ago

Martin Shkreli Takes Aim At Capricor — Stock Sinks


Capricor Therapeutics Earnings Call Transcript: Q3 2025

Nov 10, 2025, 4:30 PM EST - 6 months ago

Capricor Therapeutics Earnings Call Transcript: Q3 2025


Capricor Therapeutics Transcript: Study Update

Sep 25, 2025, 8:30 AM EDT - 7 months ago

Capricor Therapeutics Transcript: Study Update


Capricor Therapeutics Earnings Call Transcript: Q2 2025

Aug 11, 2025, 4:30 PM EDT - 9 months ago

Capricor Therapeutics Earnings Call Transcript: Q2 2025


Capricor's Lead Duchenne Therapy Hits FDA Regulatory Roadblock

Jul 11, 2025, 9:03 AM EDT - 10 months ago

Capricor's Lead Duchenne Therapy Hits FDA Regulatory Roadblock


Capricor Therapeutics Transcript: Study Update

Jul 11, 2025, 8:30 AM EDT - 10 months ago

Capricor Therapeutics Transcript: Study Update


Capricor Therapeutics Earnings Call Transcript: Q1 2025

May 13, 2025, 4:30 PM EDT - 1 year ago

Capricor Therapeutics Earnings Call Transcript: Q1 2025


Capricor Therapeutics Earnings Call Transcript: Q4 2024

Mar 19, 2025, 4:30 PM EDT - 1 year ago

Capricor Therapeutics Earnings Call Transcript: Q4 2024


Capricor Therapeutics Earnings Call Transcript: Q3 2024

Nov 13, 2024, 4:30 PM EST - 1 year ago

Capricor Therapeutics Earnings Call Transcript: Q3 2024


Capricor Therapeutics Transcript: Study Update

Sep 24, 2024, 8:30 AM EDT - 1 year ago

Capricor Therapeutics Transcript: Study Update


Capricor Therapeutics Earnings Call Transcript: Q2 2024

Aug 7, 2024, 4:30 PM EDT - 1 year ago

Capricor Therapeutics Earnings Call Transcript: Q2 2024


Capricor Therapeutics Earnings Call Transcript: Q1 2024

May 13, 2024, 4:30 PM EDT - 2 years ago

Capricor Therapeutics Earnings Call Transcript: Q1 2024


Capricor Therapeutics Transcript: FDA Announcement

Apr 29, 2024, 8:30 AM EDT - 2 years ago

Capricor Therapeutics Transcript: FDA Announcement


Capricor Therapeutics Earnings Call Transcript: Q4 2023

Feb 29, 2024, 4:30 PM EST - 2 years ago

Capricor Therapeutics Earnings Call Transcript: Q4 2023


Capricor Therapeutics Earnings Call Transcript: Q3 2023

Nov 14, 2023, 4:30 PM EST - 2 years ago

Capricor Therapeutics Earnings Call Transcript: Q3 2023


Capricor Therapeutics Transcript: FDA Announcement

Sep 29, 2023, 8:30 AM EDT - 2 years ago

Capricor Therapeutics Transcript: FDA Announcement


Capricor Therapeutics Earnings Call Transcript: Q2 2023

Aug 7, 2023, 4:30 PM EDT - 2 years ago

Capricor Therapeutics Earnings Call Transcript: Q2 2023


Capricor Therapeutics Earnings Call Transcript: Q1 2023

May 11, 2023, 4:30 PM EDT - 3 years ago

Capricor Therapeutics Earnings Call Transcript: Q1 2023


Capricor Therapeutics Earnings Call Transcript: Q4 2022

Mar 15, 2023, 4:30 PM EDT - 3 years ago

Capricor Therapeutics Earnings Call Transcript: Q4 2022


Capricor Therapeutics Earnings Call Transcript: Q3 2022

Nov 10, 2022, 1:30 PM EST - 3 years ago

Capricor Therapeutics Earnings Call Transcript: Q3 2022


Capricor Therapeutics Earnings Call Transcript: Q2 2022

Aug 10, 2022, 11:30 AM EDT - 4 years ago

Capricor Therapeutics Earnings Call Transcript: Q2 2022


Capricor Therapeutics Earnings Call Transcript: Q1 2022

May 10, 2022, 8:39 AM EDT - 4 years ago

Capricor Therapeutics Earnings Call Transcript: Q1 2022


Capricor Therapeutics Earnings Call Transcript: Q4 2021

Mar 10, 2022, 5:45 AM EST - 4 years ago

Capricor Therapeutics Earnings Call Transcript: Q4 2021


Capricor Therapeutics Earnings Call Transcript: Q3 2021

Nov 9, 2021, 10:20 AM EST - 4 years ago

Capricor Therapeutics Earnings Call Transcript: Q3 2021


Capricor Therapeutics Earnings Call Transcript: Q2 2021

Aug 12, 2021, 11:58 AM EDT - 5 years ago

Capricor Therapeutics Earnings Call Transcript: Q2 2021


Capricor Therapeutics Earnings Call Transcript: Q1 2021

May 13, 2021, 11:27 AM EDT - 5 years ago

Capricor Therapeutics Earnings Call Transcript: Q1 2021


nickiead
nickiead Apr. 28 at 9:01 PM
$CAPR Makary says search has gone extremely well with some terrific candidates. His preference, according to several sources is Hemmati, so I expect he will get the position.
1 · Reply
UncleB13
UncleB13 Apr. 28 at 8:02 PM
$CAPR as I suspected
8 · Reply
Macme
Macme Apr. 28 at 7:35 PM
$CAPR Late spike? Let’s see
0 · Reply
bronx24bomber
bronx24bomber Apr. 28 at 7:04 PM
$CAPR This has gone from green to red in the last hour on multiple occasions. Lets hope we get the opposite today.
0 · Reply
WBinthehouse
WBinthehouse Apr. 28 at 6:58 PM
$CAPR The highest price ever paid for a Priority Review Voucher is $350 million. This record was set in 2015 when AbbVie purchased a Rare Pediatric Disease PRV from United Therapeutics. PRVs are FDA issued vouchers that allow a company to receive priority FDA review for a new drug application, and they can be sold or transferred to other companies. They are especially valuable for rare disease drugs or certain tropical disease treatments.
1 · Reply
wkee
wkee Apr. 28 at 6:42 PM
$CAPR get your popcorn !! 🍿
1 · Reply
Atmwireless
Atmwireless Apr. 28 at 6:40 PM
0 · Reply
aricray
aricray Apr. 28 at 6:40 PM
$CAPR added
0 · Reply
ys95
ys95 Apr. 28 at 6:36 PM
$CAPR well looks like we are finally gonna hit the 3month trendline. Good news is, it now sits at $33.40ish. (It’s moved up a bunch these past couple of weeks) it would also be great if we only get close and not touch it. Time will tell.
0 · Reply
Marthvadir
Marthvadir Apr. 28 at 6:32 PM
$CAPR Added 40
0 · Reply
Stonksgoingup
Stonksgoingup Apr. 28 at 6:12 PM
0 · Reply
Bentradez
Bentradez Apr. 28 at 6:05 PM
$CAPR following the market until we hear something new. Just holding and excited to see what’s to come 🍪
0 · Reply
patatechaude
patatechaude Apr. 28 at 3:25 PM
$CAPR The news we're actually waiting for is "approval". And it's closer by the day. May?
1 · Reply
Fidusen
Fidusen Apr. 28 at 3:14 PM
$CAPR looks like another 35 day - not for long though
0 · Reply
wkee
wkee Apr. 28 at 3:00 PM
$CAPR 80.00 with fda news of new guy!!! Let's go Linda !!
2 · Reply
crestycrust
crestycrust Apr. 28 at 2:54 PM
$CAPR I wonder if the vetting process is taking a while with the new guy having private industry experience. If that’s the case we may see an interim announced Friday.
1 · Reply
WBinthehouse
WBinthehouse Apr. 28 at 2:53 PM
$CAPR @oneg a year old article about Oppenheimer with a $22 price target PPS when it was $6 has since been revised. As of early 2026, Oppenheimer analyst Leland Gershell maintains an Outperform rating on Capricor Therapeutics (CAPR) with a price target of $54.00.
1 · Reply
ODLH
ODLH Apr. 28 at 2:51 PM
$CAPR Gemini suggested to take the replacement as a non-event, because people normally reject such an offer when they can find one at a corporate, it is low pay and boring. So probably Hemmati doesn’t even want to take it, someone will be named as an interim leader before they finally find one. OK, let’s wait for this closet peeker to fuck off and maybe Nicole comes back on 5/1?
2 · Reply
dnfrs
dnfrs Apr. 28 at 2:31 PM
$CAPR The new appointment will be announced by the government, not Capricor. It can come any time , any day . I would want to be all in when that announcement is made. And I am.
0 · Reply
oneg
oneg Apr. 28 at 2:18 PM
$CAPR Is FDA approval already fully priced in? If they receive less than 34% of total sales, is there any meaningful upside remaining? https://www.streetwisereports.com/article/2025/09/26/biotech-discovers-breakthrough-dmd-therapy-opportunity.html
5 · Reply
wkee
wkee Apr. 28 at 2:04 PM
$CAPR news coming for sure!!!
2 · Reply
WBinthehouse
WBinthehouse Apr. 28 at 2:04 PM
$CAPR Deramiocel has all the numbers pegged. The FDA is not going to say hey they are all stat sig but blah blah blah blah bla blah. lol Nah! Willis ain’t crazy! Slam dunk! Foregone conclusion an accomplished fact.
0 · Reply